These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35942602)
1. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602 [TBL] [Abstract][Full Text] [Related]
2. Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone. Winans SA; Luce AM; Hasbun R Infection; 2013 Aug; 41(4):769-74. PubMed ID: 23686435 [TBL] [Abstract][Full Text] [Related]
3. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia. Yetmar ZA; Khodadadi RB; Go JR; Chesdachai S; Abu Saleh OM Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):423-430. PubMed ID: 36800065 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible Hamad Y; Connor L; Bailey TC; George IA Open Forum Infect Dis; 2020 Sep; 7(9):ofaa341. PubMed ID: 32908944 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive Hamad Y; Nickel KB; Olsen MA; George IA Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150 [TBL] [Abstract][Full Text] [Related]
6. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234 [TBL] [Abstract][Full Text] [Related]
7. Ceftriaxone versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia. Mohamed A; Bennett N; Ploetz J; Aragon L; Kennedy K; Boyd S Int J Antimicrob Agents; 2022 Sep; 60(3):106632. PubMed ID: 35787919 [TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253 [TBL] [Abstract][Full Text] [Related]
9. Twice daily cefazolin is effective for treatment of serious methicillin-sensitive Birrell MT; Fuller A Ther Adv Infect Dis; 2019; 6():2049936119882847. PubMed ID: 31839941 [TBL] [Abstract][Full Text] [Related]
10. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections. Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335 [TBL] [Abstract][Full Text] [Related]
11. A Comparison of Cefazolin Versus Ceftriaxone for the Treatment of Methicillin-Susceptible Carr DR; Stiefel U; Bonomo RA; Burant CJ; Sims SV Open Forum Infect Dis; 2018 May; 5(5):ofy089. PubMed ID: 30568987 [TBL] [Abstract][Full Text] [Related]
12. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation. Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787 [TBL] [Abstract][Full Text] [Related]
13. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia. Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia. Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001 [TBL] [Abstract][Full Text] [Related]
15. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins. Li J; Echevarria KL; Traugott KA Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690 [TBL] [Abstract][Full Text] [Related]
16. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus. Wieland BW; Marcantoni JR; Bommarito KM; Warren DK; Marschall J Clin Infect Dis; 2012 Mar; 54(5):585-90. PubMed ID: 22144536 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections. Patel UC; McKissic EL; Kasper D; Lentino JR; Pachucki CT; Lee T; Lopansri BK Int J Clin Pharm; 2014 Dec; 36(6):1282-9. PubMed ID: 25186790 [TBL] [Abstract][Full Text] [Related]
18. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Li J; Echevarria KL; Hughes DW; Cadena JA; Bowling JE; Lewis JS Antimicrob Agents Chemother; 2014 Sep; 58(9):5117-24. PubMed ID: 24936596 [TBL] [Abstract][Full Text] [Related]
19. Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus. Gern BH; Greninger AL; Weissman SJ; Stapp JR; Tao Y; Qin X Ann Clin Microbiol Antimicrob; 2018 Feb; 17(1):5. PubMed ID: 29463249 [TBL] [Abstract][Full Text] [Related]